Please login to the form below

Not currently logged in
Email:
Password:

The evolving biosimilars market

Safety and efficacy doubts remain a challenge

Laurent ChanrouxThe biosimilar market has continued to evolve rapidly in 2015, with the EMA's revised overarching guidelines on biosimilars coming into force and the FDA's approval of biosimilar filgrastim through the new biosimilars pathway (established under the Biologics Price Competition and Innovation Act).

Although these key regulatory developments are expected to greatly facilitate the approval of biosimilars in the near future, recent research from Research Partnership's Therapy Watch revealed that only 47% of rheumatologists interviewed would prescribe a biosimilar within the next six months, and that these agents might eventually only account for 12% of their biologic patients.

Our panel also highlighted the continued need for biosimilar manufacturers to address the remaining doubts about the safety and efficacy of these drugs and work with regulatory agencies and physician organisations to address the lack of clear treatment guidelines governing their use.

Laurent Chanroux

Laurentc@researchpartnership.com
+44 (0)20 8069 5016

21st July 2015

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...